Mersana Therapeutics Inc. [NASDAQ: MRSN] closed the trading session at $24.17 on 09/14/20. The day’s price range saw the stock hit a low of $21.56, while the highest price level was $24.60. The company report on September 10, 2020 that Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress.
– Company to Host Conference Call and Webcast Featuring Study Investigator, Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET -.
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present updated interim data from the ovarian cancer cohort of the ongoing Phase 1 expansion study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b. These data will be presented in an on-demand e-poster display at the 2020 European Society of Medical Oncology (ESMO) Virtual Congress and will be available beginning Thursday, September 17, 2020.
The stocks have a year to date performance of 321.82 percent and weekly performance of 49.20 percent. The stock has been moved at 348.42 percent over the last six months. The stock has performed 32.15 percent around the most recent 30 days and changed 14.01 percent over the most recent 3-months.
If compared to the average trading volume of 770.89K shares, MRSN reached to a volume of 5178022 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Mersana Therapeutics Inc. [MRSN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRSN shares is $27.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRSN stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Mersana Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 29, 2020. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $7 to $12. The new note on the price target was released on January 21, 2020, representing the official price target for Mersana Therapeutics Inc. stock.
The Average True Range (ATR) for Mersana Therapeutics Inc. is set at 1.53, with the Price to Sales ratio for MRSN stock in the period of the last 12 months amounting to 960.69. The Price to Book ratio for the last quarter was 5.37, with the Price to Cash per share for the same quarter was set at 4.31.
MRSN stock trade performance evaluation
Mersana Therapeutics Inc. [MRSN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 49.20. With this latest performance, MRSN shares gained by 32.15% in over the last four-week period, additionally plugging by 348.42% over the last 6 months – not to mention a rise of 1199.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRSN stock in for the last two-week period is set at 70.87, with the RSI for the last a single of trading hit 78.88, and the three-weeks RSI is set at 65.93 for Mersana Therapeutics Inc. [MRSN]. The present Moving Average for the last 50 days of trading for this stock 19.95, while it was recorded at 19.36 for the last single week of trading, and 12.19 for the last 200 days.
Mersana Therapeutics Inc. [MRSN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Mersana Therapeutics Inc. [MRSN] shares currently have an operating margin of -71.69. Mersana Therapeutics Inc.’s Net Margin is presently recorded at -66.97.
Return on Total Capital for MRSN is now -63.42, given the latest momentum, and Return on Invested Capital for the company is -61.14. Return on Equity for this stock declined to -64.76, with Return on Assets sitting at -30.32. When it comes to the capital structure of this company, Mersana Therapeutics Inc. [MRSN] has a Total Debt to Total Equity ratio set at 10.38. Additionally, MRSN Total Debt to Total Capital is recorded at 9.40, with Total Debt to Total Assets ending up at 7.56. Long-Term Debt to Equity for the company is recorded at 6.58, with the Long-Term Debt to Total Capital now at 5.96.
Reflecting on the efficiency of the workforce at the company, Mersana Therapeutics Inc. [MRSN] managed to generate an average of -$339,855 per employee. Receivables Turnover for the company is 183.54 with a Total Asset Turnover recorded at a value of 0.45.Mersana Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.20 and a Current Ratio set at 13.20.
Earnings per share (EPS) analysis for Mersana Therapeutics Inc. [MRSN] stock
With the latest financial reports released by the company, Mersana Therapeutics Inc. posted -0.35/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 5.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRSN.
Mersana Therapeutics Inc. [MRSN]: Insider Ownership positions
There are presently around $1,649 million, or 96.20% of MRSN stock, in the hands of institutional investors. The top three institutional holders of MRSN stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 7,959,520, which is approximately -33.469% of the company’s market cap and around 0.80% of the total institutional ownership; BLACKROCK INC., holding 7,137,740 shares of the stock with an approximate value of $172.52 million in MRSN stocks shares; and AVORO CAPITAL ADVISORS LLC, currently with $157.1 million in MRSN stock with ownership of nearly New of the company’s market capitalization.
Positions in Mersana Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 108 institutional holders increased their position in Mersana Therapeutics Inc. [NASDAQ:MRSN] by around 41,186,898 shares. Additionally, 28 investors decreased positions by around 13,273,691 shares, while 4 investors held positions by with 13,749,422 shares. The mentioned changes placed institutional holdings at 68,210,011 shares, according to the latest SEC report filing. MRSN stock had 56 new institutional investments in for a total of 26,827,053 shares, while 6 institutional investors sold positions of 5,129,903 shares during the same period.